INTRODUCTION
Molecular biomarkers have rapidly become a buzzword in pulmonary medicine. Clinical scientists and drug companies repeatedly mention that they are the most critical missing link in improving drug development in chronic lung disease in general, and idiopathic pulmonary fibrosis (IPF) in particular. The reason for this is quite obvious -IPF, a chronic, progressive and frequently lethal interstitial lung disease (ILD) of unknown origin [1, 2] , still presents a challenge in clinical research because of its variable and unpredictable course and the lack of easily reproducible surrogate endpoints for patient relevant outcomes [3] . In fact, it is highly common that speakers at international conferences and authors of reviews and position statements mention the dire need for biomarkers and bemoan the lack of reproducible and validated biomarkers [4 & ,5 & ], often ignoring the emerging body of work suggesting that the peripheral blood is indicative of disease presence, stage and prognosis in IPF [6] .
Molecular biomarkers can be defined as molecules or genes that carry information about the health or disease state of the individual assayed. Generally speaking, biomarkers can be divided into several classes based on the type of the information that they provide. Diagnostic biomarkers allow the distinction of one disease from the other, and can be used in disease classification and diagnosis. Disease susceptibility markers -most often gene mutations and polymorphisms associated with the diseaseare often included with diagnostic markers, but in fact differ because in the healthy individual they just indicate an increased risk and their diagnostic value is unclear in complex disease. Prognostic biomarkers are markers that allow the prediction of outcome, usually at the time of presentation. Diagnostic and prognostic markers should be distinguished from disease activity biomarkers that may change during the course of the disease -although in some cases they may overlap. The last group of biomarkers can be broadly defined as treatment efficacy biomarkers -these include markers that a drug is indeed affecting the pathway it is supposed to affect, markers that indicate toxicity and markers that indicate a real beneficial drug effect that could eventually be used as surrogate endpoints in drug studies.
In the current review, we focus mainly on peripheral blood biomarkers and only mention tissue and bronchoalveolar lavage fluid data when relevant. We present the recent data that supports the availability and feasibility of obtaining all previously mentioned classes of biomarkers, their relative importance as well as the steps we believe are required to move biomarkers in IPF into the clinical domain.
DIAGNOSTIC BIOMARKERS
It is the opinion of the authors of this review that diagnostic biomarkers are, at this stage, the least pressing question in biomarker discovery in IPF. The recent guidelines for diagnosis of IPF outline a clear path for diagnosis and it is yet unclear how complex is the differential diagnosis. However, it is important to mention that ruling out other conditions, potentially more responsive to immunosuppressive therapeutics, is critically important. In the context of peripheral blood markers, multiple molecules have been shown to distinguish patients with IPF from controls. These include KL-6, surfactant proteins SP-A and SP-D, matrix metalloproteases MMP-1 and MMP-7, SPP1 and YKL-40 (reviewed in [6] ). The diagnostic utility of any of these molecules is in doubt as the majority of the studies usually only compared IPF to control individuals, and when smoking controls or other ILDs were analyzed, they quite often had increased levels of the markers [7] [8] [9] . The studies usually did not include replication cohorts. Rosas et al. [10] applied a targeted proteomic approach and identified a protein signature including MMP-1, MMP-7, MMP-8, IGFBP-1 and TNFRSA1F that distinguished patients with IPF from control individuals with a sensitivity of 98.6% and a specificity of 98.1%. To determine the specificity of this signature, they demonstrated that concentrations of MMP-1 and MMP-7 were significantly higher in the plasma of patients with IPF compared with patients with chronic obstructive pulmonary disease (COPD) or sarcoidosis and differentiated IPF from hypersensitivity pneumonitis patients with a sensitivity of 96.3% and specificity of 87.2%. They did not look at the other idiopathic interstitial pneumonias (IIPs) and it seems that at least MMP-7 is also increased in patients with non-specific interstitial pneumonia [11] . The authors replicated the results in an independent cohort and demonstrated that MMP-7 was increased in individuals with subclinical ILD compared to control individuals (P ¼ 0.019) and significantly lower in full-blown IPF patients (P < 0.0001), suggesting that it could be used as potential marker for early detection. Taken together, it is obvious that while peripheral blood protein repertoire in IPF is clearly different from control individuals, the role of confounding factors such as smoking status, age and effects of chronic lung disease should be evaluated more systematically. One strategy is to directly profile tissues from patients with IPF, COPD and IIPs, and identify novel markers that are disease specific. Public availability of datasets such as the Lung Genomics Resource Consortium (LGRC) [12] that include parallel analysis of multiple chronic lung diseases as well as smoking and nonsmoking controls should allow the investigators to potentially identify novel markers that are disease specific.
DISEASE SUSCEPTIBILITY MARKERS
Multiple mutations associated with familial and sporadic forms of IPF have been reported including mutations in surfactant [13] [14] [15] and telomerase proteins [16, 17] . Mushiroda et al. [18] also identified polymorphisms within TERT [single nucleotide polymorphism (SNP) in intron 2 of the TERT gene -rs2736100] in a genome-wide association (GWA) study including a derivation cohort of 159 sporadic IPF patients and 934 controls as well
KEY POINTS
IPF is a chronic progressive and frequently lethal interstitial lung disease with an unpredictable course.
The multiple studies that identified potential diagnostic and prognostic markers in the peripheral blood were limited in size and lacked replication but together suggested a strong outcome signal in the blood.
A recently discovered MUC5B SNP is strongly associated with IPF and has been replicated in several cohorts.
Recently, a personal clinical and molecular outcome index (PCMI) that integrates clinical parameters and MMP-7 plasma concentrations and accurately predicts outcome was derived and validated.
The success of recent studies suggests that outcome prediction in IPF can be improved using peripheral blood biomarkers and thus they should be incorporated in drug study design and evaluated for the use for transplant prioritization.
as a replication cohort of 83 sporadic IPF cases and 535 controls. Interestingly, leukocyte telomere shortening was found in 24% of familial pulmonary fibrosis and 23% of sporadic IPF cases when compared to control individuals (P ¼ 2.6 Â 10 À8 ) [19] in a study that contained 201 control individuals, 59 probands with familial pulmonary fibrosis and 73 sporadic pulmonary fibrosis cases without TERT or TERC mutations. Similarly, Alder et al. [20] [32] in an independent case-control study that included 341 IPF and 801 control individuals. The minor-allele frequency was 34.3% in patients with IPF and 11.1% in controls (allelic association, P ¼ 7.6 Â 10 À40 ). The discovery of both rare mutations and common polymorphisms associated with IPF greatly improves the ability to screen the family members of patients with IPF, although additional studies are required to determine whether patients with distinct genetic predispositions exhibit distinct clinical manifestations.
PROGNOSTIC BIOMARKERS
This class of biomarkers is probably the most developed for IPF -in fact, it seems now evident that patients with IPF exhibit a biomarker profile that is indicative of outcome and contributes beyond the information that can be gleaned from the clinical presentation. Selman et al. [33] introduced in 2007 the concept of different rates of progression in IPF that demonstrated different gene-expression patterns in the lungs, an observation later replicated by Boon and colleagues [34] .
Recently, evidence has emerged in support of the peripheral blood as an informative source for outcome prediction at presentation. High blood concentrations of KL-6, also known as MUC-1, have been repeatedly shown to be predictive of decreased survival in IPF. Most of the studies are limited by cohort size and lack replication, but are still highly consistent and support the use of KL-6 in disease stratification [8] . Other notable studies include the work by Prasse et al. [35] , who demonstrated in a prospective cohort of 72 patients that serum CCL18 levels were able to predict the outcomes in IPF, the demonstration by Kinder et al. [36] in a cohort of 81 patients that serum SP-A was a predictor of early mortality in IPF, and the recent demonstration by Korthagen et al. [37] in 79 patients that high serum concentrations of YKL-40 distinguished two groups with distinct survival patterns with the hazard ratio for serum YKL-40 (cut-off 79 ng/ml) as 10.9 (95% CI 1.9-63.8, P < 0.01). Most recently, we applied a targeted proteomic approach and screened 95 proteins in the plasma of 140 IPF patients (derivation cohort) and validated the results in a replication cohort (101 patients) [38 && ]. High plasma concentrations of MMP-7, ICAM-1 and IL-8 were predictive of poor overall survival in both cohorts. We used the derivation cohort to derive a personal clinical and molecular mortality prediction index (PCMI) using the step AIC approach [39] . This index
3 ng/ml)] was highly predictive of mortality in the replication cohort with a C-index for early mortality of 84. Although it is hard to compare to other studies, this prediction seems to be substantially better than a recently proposed clinical staging system that achieved acceptable C-indexes of 69-72.3 for mortality prediction [40 & ], suggesting that the use of molecular markers will as expected improve upon clinical predictions in IPF.
Similarly, changes in circulating blood cell populations have been associated with outcome. Moeller et al. [41] demonstrated in a cohort of 51 patients that increases in circulating fibrocytes predicted poor prognosis and Gilani et al. [42] observed that downregulation of CD28 in circulating CD4 T cells was a marker of poor prognoses in a cohort of 89 IPF patients.
Overall, the outcome prediction based on the peripheral blood seems to hold significant promise. Our study, the largest so far and the first to have two cohorts, demonstrated the reproducibility of the markers as well as the feasibility of integrating clinical and molecular markers. Considering the significant evidence that patients with IPF may present on distinct outcome trajectories, it seems very important that all clinical studies will collect biomarker information as results may be affected by population stratification.
DISEASE ACTIVITY MARKERS
Disease activity markers are obviously not as developed as the two previous classes of biomarkers in IPF. At this stage, there is no real definition of the disease activity of IPF -one could conceive that KL-6, SP-A and MMP-7 are markers of alveolar epithelial cell injury and CCL-18 a marker of alveolar macrophage activation, but strangely enough as yet we do not have markers for some of the processes that happen in IPF such as deposition of new collagen. Mechanistically, the biomarker that may be tied most closely to disease pathogenesis is MMP-7, a pluripotent matrix metalloprotease expressed in alveolar type II cells. MMP-7 is a WNT/b-catenin pathway target molecule [43] , suggesting that increases of MMP-7 are reflective of aberrant WNT/b catenin that has been described in IPF [44, 45] . MMP-7 knockout mice are relatively protected from bleomycin-induced fibrosis, suggesting that it is mechanistically involved in the fibrosis pathways [46] . However, so far, there is no data to support MMP-7 as a marker of disease activity.
Another way to look at the markers of disease activity is to identify the markers of acute exacerbations of IPF (AE-IPF), episodes of decline in respiratory status without an identifiable cause [47] , that lead to significant mortality [48] . Of the previous markers mentioned, KL-6 has been mostly widely studied in this context [8, 49, 50] . It seems that AE-IPF are associated with increases in blood KL-6, although the mechanisms are not clear. We compared the gene expression in the lungs of patients with AE-IPF lungs to stable IPF [51] and identified 579 differentially expressed genes, and did not find any indication of infectious or inflammatory cause. We did find an increase in a-defensins, a group of innate antimicrobial peptides, in the mRNA levels as well as in the plasma protein level of AE-IPF patients, suggesting that they should be evaluated as biomarkers for acute exacerbations [52] .
DRUG EFFICACY BIOMARKERS
At this stage, there are no drug efficacy biomarkers in IPF. However, our knowledge of disease mechanisms as well the drugs that are now being evaluated may allow some speculation. For instance, one could advocate that markers of TGF-b activation would be assessed in a study that aims to reduce the local TGF-b [53] , downstream effects of kinase inhibition would be assessed in a study that involves receptor tyrosine kinase inhibition [54] or that MMP-7 levels would be followed if a WNT inhibitor was studied (the authors do not know of such study). At this stage -all of these suggestions are speculative, but insistence by the scientific community on drug efficacy markers will greatly enhance our understanding of IPF, the mechanisms of action of certain drugs and, most importantly, whether drug studies fail because the drug actually is not effective or because of other confounders.
CONCLUSION
In this review, we presented the overwhelming evidence that the peripheral blood is highly informative with regard to disease presence, stage and outcome. The most significant advance in the last year is the addition of two sets of validated markers: one is the replicated gene association of MUC5B polymorphism with IPF, and the other is the derivation of the combined clinical and molecular outcome index (PCMI). In both cases, the strength lies in the relative size of the cohorts and the replication. However, it is critical to note that the majority of markers have not been formally replicated and that implementation of markers in drug studies and clinical practice will require a coordinated validation effort. Standardization of methods, recruitment of large numbers of highly phenotyped individuals and relevant controls, including other chronic lung diseases, prospective longitudinal follow-up and sampling, and an integrated approach that incorporates validation with discovery will be required. This is a significant effort and obviously beyond the capacity of a single center; moreover, in the current funding atmosphere such an effort will not be sustainable if dependent on NIH funding. Thus, it is recommended that an IPF biomarker consortium consisting of industry, patient advocacy organizations and the scientific community should be organized. Under such a structure, companies and institutions will be able to contribute samples and clinical information for the validation of currently known biomarkers, while still maintaining the analysis of their favorite markers and benefitting from a much larger pool of patients. On the basis of a significant and impressive body of knowledge that was derived under less optimal research conditions, it seems that a community-wide study will indeed identify all classes of biomarkers and transform our research and management of IPF. 5.
